Inmatics NV (IMTX) stock prices were up by 2.25% as of the market closing on September 9th, 2021. This brought the price per share up to USD$15.46 at the end of the trading day. Subsequent premarket fluctuations saw the stock surge by 6.60%, bringing it up to USD$16.48.
ACTengine Program Development
The second quarter of fiscal 2021 saw IMTX stock report a significant increase in patient enrollment in its ACTengine programs. Initial results for the programs were positive in the first quarter of fiscal 2021. Following this success, the company is working towards announcing more advanced data in the second half of 2021. These data include, but are not limited to, safety, biological activity, and the assessment of anti-tumor activity for a myriad of various cancer indications.
Clinical Trial Application
The company is also allocating resources towards moving its second therapeutic modality towards the clinic. The entirety of the IMA401 data set is highly encouraging, with IMTX setting the stage to submit a Clinical Trial Application. The application follows collaborations with regulatory authorities and is expected for the fourth quarter of fiscal 2021. The company’s TCER pipeline is additionally consolidated by its second TCR Bispecifics program, IMA402. Preclinical proof-of-concept data for the program was recently presented.
IMTX Stock’s Revenue Reports
Total revenues for the second quarter of fiscal 2021 came in at USD$6.2 million, generated by revenue from collaboration agreements. This is comparable to the USD$8.2 million reported for the prior-year quarter. The end of Q2 2021 also saw IMTX stock report a solid liquidity position. Cash and cash equivalents, and other financial assets were reported in the amount of USD$229.1 million as of June 30th, 2021. This is comparable to the USD$257.5 million reported as of March 31st, 2021.
IMTX Stock’s R&D Expenses
Research and development costs for the 2021 quarter were reported at USD$24.1 million. This is an increase from the USD$19.7 million reported for the prior year quarter. The year over year difference was largely driven by an expansion of clinical activities for the ACTengine IMA200 series. Further consolidating the yearly difference was GMP manufacturing for the company’s TCER compound, IMA401.
Future Outlook for IMTX Stock
IMTX stock reported a promising quarter, the momentum of which has continued to propel the company’s trajectory of success. The company is poised to capitalize on the expanded scope of its business as it ushers in further organic and unprecedented growth. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal. This is hoped to result in significant and sustained increases in shareholder value.
